Stock Research Report: NTPC, Lupin, NCC and Ahluwalia Contracts

Four very different businesses — a power major, a pharma exporter and two construction contractors — share one theme right now: each trades at a discount to its immediate sector peers. Here's a sourced snapshot of NTPC, Lupin, NCC and Ahluwalia Contracts.

Snapshot

NTPC (NSE: NTPC) — India's power major, trading at a PSU discount

Market cap ~₹3.3 lakh crore, P/E ~12x versus peers Power Grid (~16x) and NHPC (~20x). Q1 FY27 consolidated PAT rose about 13% YoY to roughly ₹6,900 crore on 7.8% revenue growth. Group capacity has crossed 89 GW with a large renewable and nuclear pipeline, targeting 149 GW by 2032. Key risks: execution and funding on that capex plan, and discom payment cycles. Brokerages are mixed post-Q4: Motilal Oswal Neutral (TP ₹393), Axis Direct Buy (TP ₹430), ICICI Securities Buy (TP ₹481) — no post-Q1 FY27 target was independently verified.

Lupin (NSE: LUPIN) — pharma growth at a sector discount

P/E ~17–19x against the Nifty Pharma index's ~40x. Q1 FY27 revenue rose 33% YoY to ₹8,217 crore, its 16th straight quarter of growth, led by the US (42% of sales) and India (29%). PAT grew a slower 16% as management flagged rising US generic competition (tolvaptan, mirabegron) heading into FY27. Brokerage views vary: Motilal Oswal Neutral (TP ₹2,500), JM Financial cut its target to ₹1,806; a broader Trendlyne consensus (pre-Q1) averaged a Hold near ₹2,452.

NCC Limited (NSE: NCC) — record order book, construction-sector discount

P/E ~13x versus construction peers averaging well above 20x. Q1 FY27 revenue hit a record ₹5,800-plus crore (+12% YoY) on a consolidated order book of ₹81,214 crore (+16% YoY, about 3.5x book-to-bill). PAT growth lagged revenue on rising finance costs and leverage; management's FY27 guidance was conservative, citing uncertainty on client fund approvals. Brokerage targets, mostly pre-dating Q1 FY27, range from ICICI Direct's Buy at ₹180 to IDBI Capital's Buy at ₹225.

Ahluwalia Contracts (NSE: AHLUCONT) — debt-free, but margins under pressure

Down sharply from over ₹830 a month ago after a weak Q1 FY27: EBITDA margin fell from 8.6% to 4.3% and PAT dropped 78% YoY, hurt by a billing reduction on one hospital project and NCR wage inflation. Order book remains strong at about ₹20,664 crore (+40% YoY, roughly 4.5x revenue) and the balance sheet is virtually debt-free. Post-results, Prabhudas Lilladher maintains Buy (TP ₹930, cut from ₹1,045) while ICICI Securities is at Hold (TP ₹780).

All four operate on different cycles, but the discount each carries traces to a specific, identifiable reason — PSU status, US pricing pressure, execution risk, or a one-quarter margin miss — rather than a blanket market mispricing. None of the brokerage targets above are Money n Wealth's own view; they are third-party opinions, cited with source and approximate date, and should be read alongside each company's own filings.

FAQs

Does trading below peers mean these stocks are undervalued?

Not automatically — a valuation discount often reflects a specific, identifiable risk, not a market mispricing. It's a starting point for research, not a conclusion.

Should I buy these stocks based on this report?

No — this is a factual snapshot of public information, not a recommendation. Please do your own due diligence or speak with a qualified adviser before acting.

If you're weighing direct stock ideas like these against fund-based options, see our mutual fund planning guide and SIP planning guide. This week also saw the Hindustan Copper OFS and five new IPOs — including Symbiotec Pharmalab in the same pharma space as Lupin, and Lumino Industries in the power-equipment space alongside NTPC.

Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Brokerage ratings and target prices cited are third-party opinions, not Money n Wealth's own view, and may be dated. Past performance and analyst estimates do not guarantee future returns. Please consult your financial adviser and read company filings before investing. Investments are subject to market risks.